Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright's price target indicates a potential upside of 154.55% from the company's previous close.
Armata Pharmaceuticals Stock Performance
Shares of NYSEAMERICAN:ARMP traded up $0.50 during midday trading on Tuesday, reaching $2.75. 33,775 shares of the company traded hands, compared to its average volume of 12,313. Armata Pharmaceuticals has a 12 month low of $1.93 and a 12 month high of $4.48. The firm has a market cap of $99.50 million, a price-to-earnings ratio of -1.08 and a beta of 0.80.
Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.13). Equities analysts predict that Armata Pharmaceuticals will post -1.02 EPS for the current fiscal year.
About Armata Pharmaceuticals
(
Get Free Report)
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Featured Stories
Before you consider Armata Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Armata Pharmaceuticals wasn't on the list.
While Armata Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
